FoundationOne next-generation sequencing showed that her PD-L1 tumor proportion score was 0%, tumor mutation burden was low, and there were no reportable alterations in BRAF, ERBB2, KRAS, or NRAS. This evidence concerns the gene KRAS and neoplasm.